Urine colorimetry for therapeutic drug monitoring of pyrazinamide during tuberculosis treatment
Isaac Zentner, Chawangwa Modongo, Nicola M Zetola, Jotam G Pasipanodya, Shashikant Srivastava, Scott K Heysell, Stellah Mpagama, Hans P Schlect, Tawanda Gumbo, Gregory P Bisson, Christopher Vinnard, Isaac Zentner, Chawangwa Modongo, Nicola M Zetola, Jotam G Pasipanodya, Shashikant Srivastava, Scott K Heysell, Stellah Mpagama, Hans P Schlect, Tawanda Gumbo, Gregory P Bisson, Christopher Vinnard
Abstract
Objectives: Pyrazinamide is a key drug in the first-line treatment regimen for tuberculosis, with a potent sterilizing effect. Although low pyrazinamide peak serum concentrations (Cmax) are associated with poor treatment outcomes, many resource-constrained settings do not have sufficient laboratory capacity to support therapeutic drug monitoring (TDM). The objective of this study was to determine whether a colorimetric test of urine can identify tuberculosis patients with adequate pyrazinamide exposures, as defined by serum Cmax above a target threshold.
Methods: In the derivation study of healthy volunteers, three dose sizes of pyrazinamide were evaluated, and intensive pharmacokinetic blood sampling was performed over an 8-h period, with a timed urine void at 4h post-dosing. Pyrazinamide in urine was isolated by spin column centrifugation with an exchange resin, followed by colorimetric analysis; the absorbance peak at 495nm was measured. The urine assay was then evaluated in a study of 39 HIV/tuberculosis patients in Botswana enrolled in an intensive pharmacokinetic study. Receiver operating characteristics (ROC) curves were used to measure diagnostic accuracy. The guideline-recommended pyrazinamide serum Cmax target of 35mg/l was evaluated in the primary analysis; this target was found to be predictive of favorable outcomes in a clinical study. Following this, a higher serum Cmax target of 58mg/l was evaluated in the secondary analysis.
Results: At the optimal cut-off identified in the derivation sample, the urine colorimetric assay was 97% sensitive and 50% specific to identify 35 of 39 HIV/tuberculosis patients with pharmacokinetic target attainment, with an area under the ROC curve of 0.81 (95% confidence interval 0.60-0.97). Diagnostic accuracy was lower at the 58mg/l serum Cmax target, with an area under the ROC curve of 0.68 (95% confidence interval 0.48-0.84). Men were less likely than women to attain either serum pharmacokinetic target.
Conclusions: The urine colorimetric assay was sensitive but not specific for the detection of adequate pyrazinamide pharmacokinetic exposures among HIV/tuberculosis patients in a high-burden setting.
Keywords: Human immunodeficiency virus; Pharmacokinetics; Point-of-care testing; Pyrazinamide; Tuberculosis.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.
Source: PubMed